Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
17/06/2025 11:48
June 17 (Reuters) - Eli Lilly LLY.N will acquire Verve Therapeutics VERV.O for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai) ((Sriparna.Roy@thomsonreuters.com;))